Are In Vivo Cell Therapies the Future?
Friday, May 31, 2024 05:00 PM - 06:00 PM
Room 211
Concurrent Session
Chair
Cell therapies, from cancer to monogenetic diseases, continue to demonstrate clinical benefit. However, recent regulatory approvals notwithstanding, with for example six approved CAR-T products in US, only a small portion of eligible patients are able to avail of approved CAR-T products due to multiple confounding factors and no ability to impact the needle-to-needle time for providing therapies to patients with rapidly advancing disease. Similar challenges also exist in delivery of engineered stem cell products for monogenetic diseases where patients are subjected to mobilization, toxic chemotherapy regimens, and concomitant stem cell transplant with its associated co-morbidity and co-mortality. Therefore, there is an urgent need to develop novel manufacturing and quality paradigms that permit same day patient treatment, leading to development of engineered cell therapies in vivo.
This session will focus on advances in transfusion medicine, novel modalities for cell engineering, novel delivery technologies that permit in vivo cell engineering and challenge us to debate and define the future roadmap for In Vivo Cell Therapies.
- Madhusudan V. Peshwa, PhD, Tessera Therapeutics, United States
- Madhusudan V. Peshwa, PhD, Tessera Therapeutics, United States,
- Christopher Wegener, MS, BME, Fresenius Kabi, United States, "Point-of-Care/Bedside Manufacture & Delivery of CGT Products"
- Dalip Sethi, PhD, MBA, Terumo BCT, United States
- David Peritt, PhD, Lupagen, United States
Cell therapies, from cancer to monogenetic diseases, continue to demonstrate clinical benefit. However, recent regulatory approvals notwithstanding, with for example six approved CAR-T products in US, only a small portion of eligible patients are able to avail of approved CAR-T products due to multiple confounding factors and no ability to impact the needle-to-needle time for providing therapies to patients with rapidly advancing disease. Similar challenges also exist in delivery of engineered stem cell products for monogenetic diseases where patients are subjected to mobilization, toxic chemotherapy regimens, and concomitant stem cell transplant with its associated co-morbidity and co-mortality. Therefore, there is an urgent need to develop novel manufacturing and quality paradigms that permit same day patient treatment, leading to development of engineered cell therapies in vivo.
This session will focus on advances in transfusion medicine, novel modalities for cell engineering, novel delivery technologies that permit in vivo cell engineering and challenge us to debate and define the future roadmap for In Vivo Cell Therapies.
